AIM
ATNM icon

Acrospire Investment Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Acrospire Investment Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-63
Closed -$2K – 113
2017
Q2 		$2K Sell
63
-130
-67% -$5.44K ﹤0.01% 2058
2017
Q1 		$9K Buy
+193
New +$7.41K 0.01% 1882
2016
Q4 		– Sell
-187
Closed -$8K – 2188
2016
Q3 		$8K Sell
187
-60
-24% -$3.08K 0.01% 1745
2016
Q2 		$13K Buy
247
+210
+568% +$11.7K 0.01% 1674
2016
Q1 		$2K Buy
+37
New +$2.34K ﹤0.01% 1932

Other funds holding ATNM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acrospire Investment Management's ATNM Position: Q3 2017 in Review

Acrospire Investment Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2017, closing a stake of 63 shares — an estimated $2K sold.

Acrospire Investment Management first reported a position in ATNM in Q1 2016 and held it in 5 quarters. The position peaked at $13K in Q2 2016. 31 funds tracked by Wall St. Rank hold ATNM as of Q3 2017.

  • Acrospire Investment Management reported no remaining Actinium Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 63 Actinium Pharmaceuticals shares in Q3 2017, an estimated $2K.
  • Acrospire Investment Management first reported a position in Actinium Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Actinium Pharmaceuticals position peaked at $13K in Q2 2016.
  • 31 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.